{"id":"W4410212347","doi":"10.1177/17588359251332154","title":"Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Agricultural Research Institute of Ontario; McMaster University; University of Alberta; University of British Columbia; Ottawa Hospital; University of Ottawa","funders":"Debiopharm","keywords":"Avelumab; Medicine; Lung cancer; Tolerability; Internal medicine; Oncology; Adverse effect; Cancer; Response Evaluation Criteria in Solid Tumors; Nivolumab; Toxicity; Phases of clinical research; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008946576,0.0003771384,0.0009598052,0.0002369617,0.00009804205,0.00002229895,0.00051574,0.0003315254,0.00003822563],"category_scores_gemma":[0.00007200253,0.0003019499,0.00003131391,0.0004925991,0.000209081,0.00005872518,0.0002842655,0.0003599616,4.076925e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002436921,"about_ca_system_score_gemma":0.0009287876,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002245636,"about_ca_topic_score_gemma":0.009392157,"domain_scores_codex":[0.9968076,0.0006763841,0.0008001028,0.0009703987,0.0002658301,0.0004796766],"domain_scores_gemma":[0.9988062,0.0002412127,0.0002535571,0.0004506138,0.00006754135,0.0001808866],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.04647457,0.006809917,0.002964017,0.00007169067,0.0001279057,0.0002822699,0.001580734,0.005246558,0.2847295,0.00001719651,0.000003359962,0.6516923],"study_design_scores_gemma":[0.7450006,0.0229369,0.04230792,0.002105369,0.0006229084,0.00002801041,0.01369406,0.1198191,0.04247145,0.0007030824,0.008116458,0.002194189],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9611352,0.02446178,0.01151912,0.0002411389,0.0002842864,0.002194992,0.00001219883,0.00001428265,0.0001370066],"genre_scores_gemma":[0.9753487,0.02140984,0.001964153,0.0005546071,0.00005125169,0.0004608091,0.0001247923,0.00003421513,0.00005164805],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.698526,"threshold_uncertainty_score":0.9999433,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02980140825103593,"score_gpt":0.418773363259961,"score_spread":0.3889719550089251,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}